文献速递主动脉疾病

感染性主动脉瘤腔内治疗的长期结局

Long-term Outcome of Endovascular Treatment for Mycotic Aortic Aneurysm.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2017-08-18

该回顾性研究分析40例接受EVAR并术后静脉抗生素治疗的感染性主动脉瘤患者,中位随访25个月,1年和5年累积生存率分别为71%和53%,20%出现持续或复发性感染且其中75%在修复后6个月内死亡。

要点

  • EVAR可作为感染性主动脉瘤高风险患者的替代治疗选择。
  • 持续感染发生率为20%,未手术者常致命,需警惕。
  • 培养阴性患者生存趋势更好,沙门菌感染与否生存无差异。

核心结论

  • EVAR是感染性主动脉瘤可接受的替代治疗,但术后持续感染可发生且未手术时常致命。

研究设计与样本

  • 回顾性分析2009年9月至2015年4月连续40例接受EVAR并术后静脉抗生素治疗的感染性主动脉瘤患者,随访截至2015年4月30日。

主要发现

  • 修复时中位年龄73岁(范围48-88岁),男性31例(77%)。
  • 解剖位置:主动脉弓/胸部10例(25%),内脏旁7例(17%),肾下23例(57%)。
  • 10例(25%)表现为动脉瘤破裂并急诊修复,中位随访25个月(范围1-69个月)。
  • 累积1年和5年生存率分别为71%和53%,20%(n=8)出现持续或复发性感染,其中75%(n=6)在修复后6个月内死亡。

关键数值与推荐

  • 持续或复发性感染发生率为20%(n=8)。
  • 持续感染患者接受长期药物治疗,但75%(n=6)在修复后6个月内死亡。
  • 沙门菌与非沙门菌感染患者生存无差异,培养阴性患者生存趋势更好。

临床怎么用

  • 对高风险感染性主动脉瘤患者可考虑EVAR联合术后静脉抗生素治疗。
  • 术后需密切监测持续或复发性感染,一旦发生应考虑手术干预。

局限性

  • 回顾性设计,样本量40例,单中心,随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/BACKGROUND: Endovascular repair (EVAR) of mycotic aortic aneurysm (MAA) has become an alternative treatment for high risk patients. The aim of this study was to evaluate long-term survival and outcomes. METHODS: Retrospective analysis of 40 consecutive patients with MAAs undergoing EVAR and subsequent intravenous antibiotic treatment between September 2009 and April 2015. Follow-up was truncated on 30 April 2015. Uni- and multivariate logistic regression were used to assess risk factors of adverse outcomes. Cumulative survival was calculated using the Kaplan-Meier method. RESULTS: Median age at repair was 73 years (range 48-88 years) and 31 (77%) were men. Eleven (27%) patients were infected with Salmonella, 12 (30%) with non-Salmonella species, and 17 (42%) had negative cultures. Anatomical locations included the aortic arch/thoracic area in 10 (25%), the paravisceral area in seven (17%), and the infrarenal area in 23 (57%). Ten (25%) patients presented with aneurysm rupture and underwent emergency repair. Median follow-up was 25 months (range 1-69 months). Cumulative 1 and 5 year survival rates were 71% and 53%, respectively. Persistent or recurrent infection occurred in 20% (n = 8). Patients with persistent infection were treated with long-term medical therapy, but all died (75%; n = 6) within 6 months of repair. No survival difference was found between patients with or without Salmonella infections. However, there was a trend toward better survival in culture negative patients. CONCLUSION: EVAR of MAA is an acceptable alternative treatment of MAA. However, persistent infection after endovascular treatment does occur and is often fatal without surgical treatment.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Luo CM, Chan CY, Chen YS, et al. Long-term Outcome of Endovascular Treatment for Mycotic Aortic Aneurysm. Eur J Vasc Endovasc Surg. 2017. PMID: 28826996. doi:10.1016/j.ejvs.2017.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。